Drugs / HRS-2129
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07377721 | Mar → Sep 2026 overdue | diabetic polyneuropathy | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07351968 | Mar → Jul 2026 | osteoarthritis, knee | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06742840 | Dec 2024 → Jul 2025 | — | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06619392 | Oct 2024 → Jan 2025 | — | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06780267 | Mar 2025 → Mar 2026 | — | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07706777 | Aug → Oct 2026 expected | gout | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07185594 | Oct → Dec 2025 overdue | — | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-2129 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06619392 ↗ |